BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhatwadekar AD, Kansara VS, Ciulla TA. Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment. Expert Opin Investig Drugs 2020;29:237-44. [PMID: 31985300 DOI: 10.1080/13543784.2020.1723078] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhirnov VV, Velihina YS, Mitiukhin OP, Brovarets VS. Intrinsic drug potential of oxazolo[5,4-d]pyrimidines and oxazolo[4,5-d]pyrimidines. Chem Biol Drug Des 2021. [PMID: 34148293 DOI: 10.1111/cbdd.13911] [Reference Citation Analysis]
2 Sharma S, Brown CE. Microvascular basis of cognitive impairment in type 1 diabetes. Pharmacol Ther 2021;:107929. [PMID: 34171341 DOI: 10.1016/j.pharmthera.2021.107929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chatziralli I, Loewenstein A. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature. Pharmaceutics 2021;13:1137. [PMID: 34452097 DOI: 10.3390/pharmaceutics13081137] [Reference Citation Analysis]
4 Cheng KJ, Hsieh CM, Nepali K, Liou JP. Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. J Med Chem 2020;63:10533-93. [PMID: 32482069 DOI: 10.1021/acs.jmedchem.9b01033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
5 Chauhan MZ, Rather PA, Samarah SM, Elhusseiny AM, Sallam AB. Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema. Cells 2022;11:1950. [PMID: 35741079 DOI: 10.3390/cells11121950] [Reference Citation Analysis]
6 Dagnino APA, Campos MM, Silva RBM. Kinins and Their Receptors in Infectious Diseases. Pharmaceuticals (Basel) 2020;13:E215. [PMID: 32867272 DOI: 10.3390/ph13090215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
7 Neroev VV, Chesnokova NB, Kost OA, Okhotsimskaya TD, Pavlenko TA, Beznos OV, Binevsky PV, Lisovskaya OA. [Bradykinin and angiotensin-converting enzyme in serum of patients with diabetic retinopathy and the prognosis of diabetic macular edema development (pilot study)]. Probl Endokrinol (Mosk) 2021;67:13-9. [PMID: 34533010 DOI: 10.14341/probl12762] [Reference Citation Analysis]
8 Van Bergen T, Hu TT, Little K, De Groef L, Moons L, Stitt AW, Vermassen E, Feyen JHM. Targeting Plasma Kallikrein With a Novel Bicyclic Peptide Inhibitor (THR-149) Reduces Retinal Thickening in a Diabetic Rat Model. Invest Ophthalmol Vis Sci 2021;62:18. [PMID: 34677569 DOI: 10.1167/iovs.62.13.18] [Reference Citation Analysis]
9 He GH, Ma YX, Dong M, Chen S, Wang YC, Gao X, Wu B, Wang J, Wang JH. Mesenchymal stem cell-derived exosomes inhibit the VEGF-A expression in human retinal vascular endothelial cells induced by high glucose. Int J Ophthalmol 2021;14:1820-7. [PMID: 34926194 DOI: 10.18240/ijo.2021.12.03] [Reference Citation Analysis]